Ningetinib

• Description :

  Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and c-Met, VEGFR2 and Axl, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  C-Met/HGFR; TAM Receptor; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Ningetinib.html

• Purity :

  99.82

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CC1=C(C(NC2=CC(F)=C(OC3=CC=NC4=C3C=CC(OCC(C)(O)C)=C4)C=C2)=O)C(N(C5=CC=CC=C5)N1C)=O

• Molecular Formula :

  C31H29FN4O5

• Molecular Weight :

  556.58

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74 (19 Suppl) :Abstract nr 1755.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  Axl; VEGFR2/KDR/Flk-1

• CAS Number :

  [1394820-69-9]